April 29, 2008 - Sorin Group Cardiac Rhythm Management completed the first implant in a clinical trial of its new-generation PARADYM 8770 sonR cardiac resynchronization therapy defibrillator (CRT-D), introducing a technology based on hemodynamic response for continuous adjustment of cardiac resynchronization.
This system contains a technology named sonR designed to adjust CRT delivery based on hemodynamic response as opposed to conventional CRT-D devices, that monitor the electrical activity of the heart. PARADYM sonR is the first device delivering continuous management of resynchronization therapy during patients' everyday life.
What is unique about the defibrillator, according to the manufacturer, is that while conventional devices look at the heart as a clock, new PARADYM sonR looks at the heart as a pump, measuring vibrations generated by heart contraction. Thanks to this innovative approach, we provide the medical community and their patients with a completely new system, and this is in line with our vision to become an innovative leader in hemodynamic management of heart failure.
The new device with its son functionality is designed to measure and evaluate the performance of the cardiac pump, and to adapt the CRT settings to the patients' cardiac status automatically and recurrently during patients' everyday life.
A multi-centre clinical trial including 150 patients is currently being conducted across Europe. The first sonR systems, the PARADYM son CRT-D, including the sonR FIX atrial lead, were implanted by Professor Angelo Auricchio from Cardiocentro Ticino in Lugano, Switzerland, Peter Paul Delnoy, M.D., from Isala Clinics in Zwolle, Netherlands, and Neil Sulke, M.D., from Eastbourne General Hospital in the United Kingdom.
The PARADYM family also includes a single-chamber (VR 8250), and a dual-chamber (DR 8550) implantable cardioverter defibrillator for the management of arrhythmias.
For more information: www.soringroup-usa.com
February 12, 2024 
